Functional activity of antibodies after immunization of Finnish and Israeli infants with an 11-valent pneumococcal conjugate vaccine

Tomi K. Wuorimaa; Ron Dagan; Fabrice Bailleux; Raili Haikala; Nina Ekström; Juhani Eskola; Mansour Yaich; Helena Käyhty

doi:10.1016/j.vaccine.2005.06.023

Functional activity of antibodies after immunization of Finnish and Israeli infants with an 11-valent pneumococcal conjugate vaccine

Tomi K. Wuorimaa, Ron Dagan, Fabrice Bailleux, Raili Haikala, Nina Ekström, Juhani Eskola, Mansour Yaich, Helena Käyhty

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Finnish and Israeli infants received an 11-valent mixed carrier pneumococcal conjugate vaccine (11PCV) with or without aluminum adjuvant at the age of 2, 4, 6, and 12 months. We measured opsonophagocytic activity (OPA) of antibodies to pneumococcal strains of serotypes 4, 6B, 14, 19F, and 23F. At 7 months, OPA was clearly detected for all the serotypes. At 13 months, OPAs increased further and the proportion of individuals with a positive OPA ranged between 81 and 100%. The adjuvant improved functional activity of antibodies to serotype 6B pneumococci. In conclusion, immunization of infants with the 11PCV induced functionally active antibodies.

Original language	English
Pages (from-to)	5328-5332
Number of pages	5
Journal	Vaccine
Volume	23
Issue number	46-47
DOIs	https://doi.org/10.1016/j.vaccine.2005.06.023
State	Published - 16 Nov 2005

Keywords

Opsonophagocytic activity
Pneumococcal conjugate vaccine

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2005.06.023

Cite this

@article{deda06bbda14418db119eb667b470eeb,

title = "Functional activity of antibodies after immunization of Finnish and Israeli infants with an 11-valent pneumococcal conjugate vaccine",

abstract = "Finnish and Israeli infants received an 11-valent mixed carrier pneumococcal conjugate vaccine (11PCV) with or without aluminum adjuvant at the age of 2, 4, 6, and 12 months. We measured opsonophagocytic activity (OPA) of antibodies to pneumococcal strains of serotypes 4, 6B, 14, 19F, and 23F. At 7 months, OPA was clearly detected for all the serotypes. At 13 months, OPAs increased further and the proportion of individuals with a positive OPA ranged between 81 and 100%. The adjuvant improved functional activity of antibodies to serotype 6B pneumococci. In conclusion, immunization of infants with the 11PCV induced functionally active antibodies.",

keywords = "Opsonophagocytic activity, Pneumococcal conjugate vaccine",

author = "Wuorimaa, {Tomi K.} and Ron Dagan and Fabrice Bailleux and Raili Haikala and Nina Ekstr{\"o}m and Juhani Eskola and Mansour Yaich and Helena K{\"a}yhty",

year = "2005",

month = nov,

day = "16",

doi = "10.1016/j.vaccine.2005.06.023",

language = "English",

volume = "23",

pages = "5328--5332",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "46-47",

}

TY - JOUR

T1 - Functional activity of antibodies after immunization of Finnish and Israeli infants with an 11-valent pneumococcal conjugate vaccine

AU - Wuorimaa, Tomi K.

AU - Dagan, Ron

AU - Bailleux, Fabrice

AU - Haikala, Raili

AU - Ekström, Nina

AU - Eskola, Juhani

AU - Yaich, Mansour

AU - Käyhty, Helena

PY - 2005/11/16

Y1 - 2005/11/16

N2 - Finnish and Israeli infants received an 11-valent mixed carrier pneumococcal conjugate vaccine (11PCV) with or without aluminum adjuvant at the age of 2, 4, 6, and 12 months. We measured opsonophagocytic activity (OPA) of antibodies to pneumococcal strains of serotypes 4, 6B, 14, 19F, and 23F. At 7 months, OPA was clearly detected for all the serotypes. At 13 months, OPAs increased further and the proportion of individuals with a positive OPA ranged between 81 and 100%. The adjuvant improved functional activity of antibodies to serotype 6B pneumococci. In conclusion, immunization of infants with the 11PCV induced functionally active antibodies.

AB - Finnish and Israeli infants received an 11-valent mixed carrier pneumococcal conjugate vaccine (11PCV) with or without aluminum adjuvant at the age of 2, 4, 6, and 12 months. We measured opsonophagocytic activity (OPA) of antibodies to pneumococcal strains of serotypes 4, 6B, 14, 19F, and 23F. At 7 months, OPA was clearly detected for all the serotypes. At 13 months, OPAs increased further and the proportion of individuals with a positive OPA ranged between 81 and 100%. The adjuvant improved functional activity of antibodies to serotype 6B pneumococci. In conclusion, immunization of infants with the 11PCV induced functionally active antibodies.

KW - Opsonophagocytic activity

KW - Pneumococcal conjugate vaccine

UR - http://www.scopus.com/inward/record.url?scp=27644492368&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2005.06.023

DO - 10.1016/j.vaccine.2005.06.023

M3 - Article

C2 - 16118028

AN - SCOPUS:27644492368

SN - 0264-410X

VL - 23

SP - 5328

EP - 5332

JO - Vaccine

JF - Vaccine

IS - 46-47

ER -

Functional activity of antibodies after immunization of Finnish and Israeli infants with an 11-valent pneumococcal conjugate vaccine

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this